BioCryst Pharmaceuticals (NASDAQ:BCRX) issued its quarterly earnings data on Thursday. The company reported ($0.17) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.17), Stock Ratings Network reports. The company had revenue of $3.50 million for the quarter, compared to the consensus estimate of $3.34 million. During the same quarter last year, the company posted ($0.09) earnings per share. BioCryst Pharmaceuticals’s revenue was down 2.8% compared to the same quarter last year. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) weekly performance is -0.83%. On last trading day company shares ended up $8.33. Analysts mean target price for the company is $16.00. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) distance from 50-day simple moving average (SMA50) is -14.61%.
Coronado Biosciences Inc. (NASDAQ:CNDO) narrowed its net loss in the first quarter to $7.4 million, or 21 cents per share, from a net loss of $8.9 million, or 35 cents, a year earlier. Coronado Biosciences Inc. (NASDAQ:CNDO) shares advanced 10.62% in last trading session and ended the day on $1.77. CNDO return on assets is -46.20%.Coronado Biosciences Inc. (NASDAQ:CNDO) quarterly performance is -33.96%.
Genetic Technologies Limited (NASDAQ:GENE) (ASX: GTG) on 30 April announced it has filed its Quarterly Activities Report for the Quarter ended March 31, 2014 in accordance with the ASX. Total cash receipts from customers during the quarter ended March 31, 2014 were $1.4 million taking the equivalent figure to more than $3.7 million for the nine-month period ended on that date. Genetic Technologies Limited (ADR) (NASDAQ:GENE) shares moved up 5.65% in last trading session and was closed at $1.12, while trading in range of $1.05 – $1.14. Genetic Technologies Limited (ADR) (NASDAQ:GENE) year to date (YTD) performance is -21.68%.
Northwest Biotherapeutics (NASDAQ:NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, on 15 April announced the closing of the first $15 million funding by a single institutional investor of the registered direct placement of up to $32 million which was announced by the Company last week. These first 2.27 million shares of common stock were sold for $6.60 per share. Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) ended the last trading day at $5.72. Company weekly volatility is calculated as 10.11% and price to cash ratio as 17.32.Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) showed a positive weekly performance of 3.62%.
Idera Pharmaceuticals Inc. (NASDAQ:IDRA) on May 13 reported its financial and operational results for the quarter ended March 31, 2014. Net loss applicable to common stockholders for the three months ended March 31, 2014 was $9.1 million, or $0.12 per diluted share, compared to a net loss applicable to common stockholders of $4.1 million, or $0.15 per diluted share, for the same period in 2013. There was nominal revenue recognized in the first quarter of 2014 and 2013. Idera Pharmaceuticals Inc. (NASDAQ:IDRA) shares advanced 11.02% in last trading session and ended the day on $2.82. IDRA return on assets is -84.10%.Idera Pharmaceuticals Inc. (NASDAQ:IDRA) quarterly performance is -42.21%.
Leave a Reply